Navigation Links
Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association

SOUTH SAN FRANCISCO, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that the company will present data from ongoing clinical studies of SNS-595 and SNS-032 at the 12th Congress of the European Hematology Association (EHA) being held June 7-10, 2007 in Vienna, Austria.

Presentations will include updated interim data from the company's Phase 1 clinical trial of SNS-595 in acute leukemias, as well as clinical data from an ongoing study of SNS-032 further detailing that compound's mechanism of action.

    -- Abstract #0489: "Pharmacokinetic/Pharmacodynamic Correlation with

       Responses in a Phase 1 Study of Patients with Relapsed/Refractory Acute

       Leukemias Treated with SNS-595" will be presented on Saturday, June 9,

       2007 from 6:00-7:15 p.m. during the Acute Myeloid Leukemia -- Clinical

       II poster session.


    -- Abstract #0742: "SNS-032 Exhibits Dose-Dependent Mechanism-Based

       Inhibition of CDK7 and CDK9 in Peripheral Blood Mononuclear Cells from

       Patients with Advanced Cancers Treated in an Ongoing Phase 1 Trial"

       will be presented on Saturday, June 9, 2007 from 6:00-7:15 p.m. during

       the Novel Therapeutics and Targeted Therapies poster session.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute leukemias for its lead compound, SNS-595. SNS-032, a selective inhibitor of cyclin-dependent kinases 7 and 9, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314, is expected to begin Phase 1 clinical trials in the first hal
'"/>




Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:12/17/2014)... Dec. 17, 2014  Beamz Interactive, Inc. (OTCQB: ... products, today announced that it has signed an ... and supplier of innovative prosthetic, orthotic and assistive ... of the agreement, RSL Steeper will promote and ... configured for use within UK residential care facilities ...
(Date:12/17/2014)... 17, 2014  IGI Laboratories, Inc. (NYSE MKT: IG; ... its offering of $125 million aggregate principal amount of ... Notes were offered and sold only to qualified institutional ... of 1933, as amended (the "Securities Act"). ... 3.75% per year, payable semiannually in arrears on June ...
(Date:12/17/2014)... 17, 2014 PCCA received the Autism ... http://bit.ly/1382OkS ) program seal for best practices in ... highlights medical practices, materials and goods that meet ... Children affected by autism often have unique ... by ingredients found in food and medicine – ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... at the J.P. Morgan 29th Annual Healthcare Conference in San ...   Interested parties may access a live audio ... the BioMarin website, www.BMRN.com .  A replay of the ...
... CLINTON, N.J., Jan. 5, 2011 Ikaria, Inc. today ... has granted INOMAX® (nitric oxide) for inhalation an additional ...  The action extends exclusivity for INOMAX from January 2013 ... submitted from three clinical trials of INOMAX in pre-term ...
Cached Medicine Technology:BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference 2FDA Extends Marketing Exclusivity for INOMAX® 2FDA Extends Marketing Exclusivity for INOMAX® 3
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
(Date:12/15/2014)... CITY, NV (PRWEB) December 15, 2014 ... powerhouse company, JM Ocean Avenue. JM Ocean Avenue ... of the Veretekk online automated marketing system. JM ... the June 2014 merger of Ocean Avenue and JM ... more than $2 Billion per year company. , “After ...
(Date:12/15/2014)... SIMpalm, a leading mobile app ... iPhone for its client, which allows users to keep ... specialized in finding the right wine. At the ... combined sensory, chemistry and wine information. All this information ... fingerprint.” Those wines that are close counterparts to one ...
(Date:12/15/2014)... By Steven Reinberg ... -- A large, new study should reassure the millions of ... the risk for breast cancer. "There is no association ... Tamimi, an associate professor of medicine at Harvard Medical School. ... for concern, and there is no protective effect either." ...
(Date:12/15/2014)... 15, 2014 Kathy McAfee, America's Marketing ... World Awards in the category of Best Blog 2014. ... for her weekly career blog Networking Ahead ... help professionals elevate their talent and influence through better ... after her book Networking Ahead for Business, has been ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... premature and more than one in ten infants in ... of the common problems associated with premature births is brittle ... fractures and rickets in the infant, and osteoporosis later in ... a training program that aims to make preemies bones stronger. ...
... State University professor will share a $3.3 million federal ... to develop an innovative method that will help smokers ... Professor Brad Schmidt and UVM psychology Professor Michael Zvolensky ... campus -- to participate in the study over the ...
... growing body of research in the field of cancer ... the launch of a major peer-reviewed scientific journal, Cancer ... new journal is the first in the world dedicated ... trials. , In the past, scientists and interested readers ...
... The long-held idea that only vertebrates have sophisticated adaptive ... many pathogens after being infected by them just once ... that many insects also have a form of immune ... they have previously encountered. This was just one of ...
... Gift of Mobility To Make Life Easier for Double ... WHO: Army Specialist Thomas Graham, 24, recent Iraqi ... at The SCOOTER Store, Baltimore,location, WHAT: The delivery ... Despite, the recent loss of both legs while deployed ...
... Dynatronics to Repurchase Up to $250,000 of the Company,s ... Dynatronics,Corporation (Nasdaq: DYNT ) today announced that ... repurchase program of the company,s common,stock by $250,000., ... board of,directors in the future of the company and ...
Cached Medicine News:Health News:Tel Aviv University gives preemies a fighting chance 2Health News:FSU researcher lands $3.3 million grant to help smokers kick habit 2Health News:AACR introduces Cancer Prevention Research 2Health News:AACR introduces Cancer Prevention Research 3Health News:Violent sex acts boost insect's immunity system 2Health News:Violent sex acts boost insect's immunity system 3Health News:Dynatronics Announces $250,000 Increase in Stock Buyback Program 2
... Raintree Billing Manager and Collections Administrator ... or de-centralized billing models and personalized ... ratios with the ability to facilitate ... claims more directly from the Onscreen ...
H2003 manage your patient records and billing processes via the Web....
... Billing system allows a practice to ... is integrated with the EMR, appointment ... interfaces with electronic clearinghouses for electronic ... set of reports, it presents practice ...
... athenaCollector™ is athenahealth's ... management solution. It provides ... billing capabilities in the ... claims and billing processes ...
Medicine Products: